Medication info

Pravaphenix Capsule

Prescription medicationApproval withdrawn
Ingredient · strength
Pravastatin Sodium›Strength being verifiedFenofibrate›Strength being verified
Manufacturer / importer
YooYoung Pharmaceutical Co., Ltd
Appearance
A hard capsule with an upper dark green and lower light green color, containing a semi-solid piece and one tablet.
Packaging
30 capsules/bottle, 90 capsules/bottle
Approval status
Approval withdrawn

MFDS item code 201206297 · Approved 2012.07.27

This product's status changed to Approval withdrawn on 2023.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of mixed dyslipidemia
Who uses it
Adults
Adult dosage
Measure creatine phosphokinase (CK) levels before administering this drug. If the CK level is significantly elevated from baseline to more than 5 times the upper limit of normal, it should return to the original level after 5~7 days. If it remains more than 5 times the upper limit of normal after 5~7 days, do not administer this drug. During treatment with this drug, regular monitoring of CK levels is recommended every 3 months during the first 12 months after starting treatment; monitoring may be continued for longer if necessary. Advise patients to consult a physician immediately if they experience unexplained muscle pain, tenderness, weakness, or cramps, and measure CK levels in such cases. If CK levels are markedly elevated (more than 5 times the upper limit of normal), discontinue this drug. It is recommended that transaminase (AST, ALT) levels be measured every 3 months during the first 12 months of treatment with this drug; monitoring may be continued for longer if necessary. If AST or ALT levels are persistently elevated to more than 3 times the upper limit of normal, discontinue this drug. During the first 12 months after starting this drug, systematic evaluation by measuring creatinine clearance every 3 months is recommended; monitoring may be continued for longer if necessary. Discontinue this drug if creatinine clearance is less than 60 mL/min. Before starting treatment, patients should follow a standard cholesterol-lowering diet and other nonpharmacological measures (such as exercise), and should continue these measures during treatment. The recommended dose is 1 capsule once daily with the evening meal. Since absorption is reduced when this drug is taken on an empty stomach, it must be taken with food. Serum lipid levels should be closely monitored in response to treatment. Serum lipid levels generally decrease rapidly after administration of this drug. If lipid levels are not adequately controlled within 3 months after administration, discontinue treatment. Elderly patients (65 years and older): Renal function should be assessed before starting treatment. Use with caution, as the safety of this drug has not been established in elderly patients aged 75 years and older. Patients with renal impairment: No dose adjustment is necessary when this drug is administered to patients with mild renal impairment. However, do not administer to patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min). Patients with hepatic impairment: No dose adjustment is necessary when this drug is administered to patients with mild hepatic impairment. However, it is not recommended for patients with moderate hepatic impairment and should not be administered to patients with severe hepatic impairment.

Ingredients

Importer
YooYoung Pharmaceutical Co., Ltd

Efficacy & effects

Treatment of mixed dyslipidemia

  • Coronary artery disease
  • abnormal LDL cholesterol levels
  • increased triglyceride levels
  • decreased HDL cholesterol levels
  • mixed dyslipidemia.
View approved original text

This medication effectively controls LDL cholesterol levels with 40 mg of Pravastatin as a monotherapy in high-risk adult patients with coronary artery disease. However, it is used in patients with mixed dyslipidemia, where triglyceride levels may rise and HDL cholesterol levels are low. Therefore, this medication helps lower LDL cholesterol levels while assisting in the management of dyslipidemia.

Dosage and Administration

Adult dosage

Measure creatine phosphokinase (CK) levels before administering this drug. If the CK level is significantly elevated from baseline to more than 5 times the upper limit of normal, it should return to the original level after 5~7 days. If it remains more than 5 times the upper limit of normal after 5~7 days, do not administer this drug. During treatment with this drug, regular monitoring of CK levels is recommended every 3 months during the first 12 months after starting treatment; monitoring may be continued for longer if necessary. Advise patients to consult a physician immediately if they experience unexplained muscle pain, tenderness, weakness, or cramps, and measure CK levels in such cases. If CK levels are markedly elevated (more than 5 times the upper limit of normal), discontinue this drug. It is recommended that transaminase (AST, ALT) levels be measured every 3 months during the first 12 months of treatment with this drug; monitoring may be continued for longer if necessary. If AST or ALT levels are persistently elevated to more than 3 times the upper limit of normal, discontinue this drug. During the first 12 months after starting this drug, systematic evaluation by measuring creatinine clearance every 3 months is recommended; monitoring may be continued for longer if necessary. Discontinue this drug if creatinine clearance is less than 60 mL/min. Before starting treatment, patients should follow a standard cholesterol-lowering diet and other nonpharmacological measures (such as exercise), and should continue these measures during treatment. The recommended dose is 1 capsule once daily with the evening meal. Since absorption is reduced when this drug is taken on an empty stomach, it must be taken with food. Serum lipid levels should be closely monitored in response to treatment. Serum lipid levels generally decrease rapidly after administration of this drug. If lipid levels are not adequately controlled within 3 months after administration, discontinue treatment. Elderly patients (65 years and older): Renal function should be assessed before starting treatment. Use with caution, as the safety of this drug has not been established in elderly patients aged 75 years and older. Patients with renal impairment: No dose adjustment is necessary when this drug is administered to patients with mild renal impairment. However, do not administer to patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min). Patients with hepatic impairment: No dose adjustment is necessary when this drug is administered to patients with mild hepatic impairment. However, it is not recommended for patients with moderate hepatic impairment and should not be administered to patients with severe hepatic impairment.

Precautions

This medication can cause muscle pains or muscle disorders, and, rarely, a serious muscle disease called rhabdomyolysis. Rhabdomyolysis can lead to rapid muscle damage resulting in kidney function issues, so any occurrence of muscle-related symptoms during treatment should be communicated to a physician immediately. In particular, patients over 70 years old, those with impaired kidney or liver function, hypothyroidism, or a history of muscle diseases should have their muscle enzyme levels checked before taking this medication. Regular blood tests to monitor muscle enzyme levels should be conducted both before and during treatment, and consultation with medical personnel should be sought immediately if there are symptoms such as muscle pain or weakness. This medication should not be administered to individuals with certain diseases, pregnant women, or children under 18 years old. Caution is required when using this medication in patients with poor liver or kidney function, those consuming excessive alcohol, or those taking immunosuppressants. Regular liver function tests are necessary during treatment, and if liver function declines, discontinuation of the medication is required. Additionally, this medication should be given cautiously to patients at risk of gallstones, pancreatitis, pulmonary diseases, or thrombosis. It is advisable to take this medication with food, and blood glucose and lipid levels should also be regularly monitored during treatment. Women who are pregnant or could become pregnant, as well as nursing mothers, should not take this medication; if pregnancy occurs while on this drug, it should be stopped immediately. In case of overdose, the patient should visit a medical facility for appropriate treatment and examination.

Side effects

  • muscle pain
  • myopathy
  • rhabdomyolysis
  • secondary renal failure
  • hypersensitivity reactions
  • worsening of diabetes
  • obesity
  • insomnia
  • nightmares
  • dizziness
Show 122 more
  • headache
  • sensory disturbances
  • palpitations
  • abdominal distension
  • abdominal pain
  • upper abdominal pain
  • constipation
  • diarrhea
  • dry mouth
  • dyspepsia
  • belching
  • abdominal rumbling
  • nausea
  • abdominal discomfort
  • vomiting
  • increased transaminases
  • liver pain
  • increased γ-GT
  • itching
  • urticaria
  • arthralgia
  • back pain
  • increased serum creatine phosphokinase
  • muscle cramps
  • musculoskeletal pain
  • muscle pain
  • pain in hands and feet
  • increased serum creatinine
  • decreased creatinine clearance
  • increased creatinine clearance
  • renal failure
  • lethargy
  • fatigue
  • influenza-like illness
  • elevated blood cholesterol
  • elevated blood triglycerides
  • increased low-density lipoprotein
  • weight gain
  • marked and persistent CK elevation
  • elevated serum transaminases
  • hyperkeratosis
  • abdominal pain
  • enteritis
  • urinary incontinence
  • kidney stones
  • lung metastasis
  • chest pain
  • pharyngitis
  • intervertebral disc disease
  • dermatitis
  • psoriasis
  • pustular rash
  • eczema
  • necrotizing fasciitis
  • sensory disturbances
  • brain disorders
  • paralysis
  • neuropathy
  • spinal stenosis
  • diabetic retinopathy
  • mental disorders
  • gastroenteritis
  • gastroesophageal reflux
  • diverticular disease
  • colitis
  • enteritis
  • benign gastrointestinal neoplasm
  • gastritis
  • liver dysfunction
  • decreased high-density lipoprotein
  • vitamin D deficiency
  • decreased creatine phosphokinase
  • hyperthyroidism
  • hypertension
  • cerebral infarction
  • rhinitis
  • cough
  • kidney cysts
  • retrograde ejaculation
  • prostatic hyperplasia
  • prostate disorders
  • female benign breast neoplasm
  • chest pain
  • bronchitis
  • shingles
  • cystitis
  • urethritis
  • laceration
  • hair loss
  • photosensitivity
  • lichen-like rash
  • muscle disorders
  • myositis
  • muscle weakness
  • rhabdomyolysis
  • polymyositis
  • tendon disorders
  • lupus erythematosus-like syndrome
  • immune-mediated necrotizing myopathy
  • abnormal urination
  • sexual dysfunction
  • increased blood urea
  • jaundice
  • fulminant hepatic necrosis
  • hepatitis
  • jaundice
  • complications of cholelithiasis
  • dermatomyositis
  • fatigue
  • nightmares
  • decreased memory
  • depression
  • interstitial lung disease
  • pancreatitis
  • pulmonary embolism
  • deep vein thrombosis
  • acute hypersensitivity
  • anaphylaxis
  • angioedema
  • DRESS syndrome
  • severe skin reactions
  • immune-mediated necrotizing myopathy

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. Moreover, it is advisable to store the medication at room temperature, avoiding extreme cold or heat, specifically between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with an upper dark green and lower light green color, containing a semi-solid piece and one tablet.

Package unit

30 capsules/bottle, 90 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.